Allison L. Germann

Allison L. Germann

Auto-generated profile, based on publicly available information

Allison L. Germann

Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
ZCZi-Wei Chen
Zi-Wei Chen
JBJohn R Bracamontes
John R Bracamontes
MBMelissa M Budelier
Melissa M Budelier
AGAllison L Germann
Allison L Germann
DSDaniel J Shin
Daniel J Shin
AEAlex S Evers
Alex S Evers
Neurosteroids are endogenous modulators of neuronal excitability and nervous system development and are being developed as anesthetic agents and treatments for psychiatric diseases. While gamma amino-butyric acid Type A (GABAA) receptors are the primary molecular targets of neurosteroid action, the structural details of neurosteroid binding to these proteins remain ill defined. We synthesized neurosteroid analogue photolabeling reagents in which the photolabeling groups were placed at three positions around the neurosteroid ring structure, enabling identification of binding sites and mapping of neurosteroid orientation within these sites. Using middle-down mass spectrometry (MS), we identified three clusters of photolabeled residues representing three distinct neurosteroid binding sites in the human α1β3 GABAA receptor. Novel intrasubunit binding sites were identified within the transmembrane helical bundles of both the α1 (labeled residues α1-N408, Y415) and β3 (labeled residue β3-Y442) subunits, adjacent to the extracellular domains (ECDs). An intersubunit site (labeled residues β3-L294 and G308) in the interface between the β3(+) and α1(−) subunits of the GABAA receptor pentamer was also identified. Computational docking studies of neurosteroid to the three sites predicted critical residues contributing to neurosteroid interaction with the GABAA receptors. Electrophysiological studies of receptors with mutations based on these predictions (α1-V227W, N408A/Y411F, and Q242L) indicate that both the α1 intrasubunit and β3-α1 intersubunit sites are critical for neurosteroid action. Neurosteroids are cholesterol metabolites produced by neurons and glial cells that participate in central nervous system (CNS) development, regulate neuronal excitability, and modulate complex behaviors such as mood. Exogenously administered neurosteroid analogues are effective sedative hypnotics and are being developed as antidepressants and anticonvulsants. Gamma amino-butyric acid Type A (GABAA) receptors, the principal ionotropic inhibitory neurotransmitter receptors in the brain, are the primary functional target of neurosteroids. Understanding the molecular details of neurosteroid interactions with GABAA receptors is critical to understanding their mechanism of action and developing specific and effective therapeutic agents. In the current study, we developed a suite of neurosteroid analogue affinity labeling reagents, which we used to identify three distinct binding sites on GABAA receptors and to determine the orientation of neurosteroid binding in each site. Electrophysiological studies performed on receptors with mutations designed to disrupt the identified binding sites showed that two of the three sites contribute to neurosteroid modulation of GABAA currents. The distinct patterns of neurosteroid affinity, binding orientation, and effect provide the potential for the development of isoform-specific agonists, partial agonists, and antagonists with targeted therapeutic effects.

3 November 2023 in Science Advances
Verified
Journal Article
Open access
FPFranziska Pohl
Franziska Pohl
AGAllison L. Germann
Allison L. Germann
JMJack Mao
Jack Mao
SHSydney Hou
Sydney Hou
BBBayode Bakare
Bayode Bakare
JHJason Held
Jason Held
The γ-aminobutyric acid–mediated (GABAergic) system participates in many aspects of organismal physiology and disease, including proteostasis, neuronal dysfunction, and life-span extension. Many of these phenotypes are also regulated by reactive oxygen species (ROS), but the redox mechanisms linking the GABAergic system to these phenotypes are not well defined. Here, we report that GABAergic redox signaling cell nonautonomously activates many stress response pathways in Caenorhabditis elegans and enhances vulnerability to proteostasis disease in the absence of oxidative stress. Cell nonautonomous redox activation of the mitochondrial unfolded protein response (mitoUPR) proteostasis network requires UNC-49, a GABA A receptor that we show is activated by hydrogen peroxide. MitoUPR induction by a spinocerebellar ataxia type 3 (SCA3) C. elegans neurodegenerative disease model was similarly dependent on UNC-49 in C. elegans . These results demonstrate a multi-tissue paradigm for redox signaling in the GABAergic system that is transduced via a GABA A receptor to function in cell nonautonomous regulation of health, proteostasis, and disease.

25 November 2024 in Journal of General Physiology
Verified
Journal Article
Open access
AGAllison L. Germann
Allison L. Germann
SPSpencer R. Pierce
Spencer R. Pierce
JSJoe Henry Steinbach
Joe Henry Steinbach
Gustav AkkGustav Akk
Gustav Akk
The maximal probability of being in an active state (PA,max) is a measure of gating efficacy for a given agonist acting on a given receptor channel. In macroscopic electrophysiological recordings, PA,max is typically estimated by comparing the amplitude of the current response to a saturating concentration of a test agonist to that of a reference agonist with known PA. Here, we describe an approach to estimate the PA,max for low-efficacy agonists at subsaturating concentrations. In this approach, the amplitude of the response to a high-efficacy control agonist applied alone is compared with the amplitude of the response to a control agonist coapplied with the low-efficacy test agonist that binds to the same site(s). If the response to the combination is larger than the response to the control agonist alone, then the PA,max of the test agonist is greater than the PA of the control response. Conversely, if the response to the control agonist is reduced upon exposure to the test agonist, then the PA,max of the test agonist is smaller than the PA of the control response. The exact PA,max of the test agonist can be determined by testing its effect at different concentrations of the control agonist to estimate the PA at which the effect changes direction. The main advantage of this approach lies in the ability to use low, subsaturating concentrations of the test agonist. The model-based predictions are supported by observations from activation of heteromeric and homomeric GABAA receptors by combinations of high- and low-efficacy orthosteric agonists.

6 June 2026 in Molecular Pharmacology
Verified
Journal Article
Open access
SPSpencer R. Pierce
Spencer R. Pierce
AGAllison L. Germann
Allison L. Germann
KTKa Tak Tsoi
Ka Tak Tsoi
Gustav AkkGustav Akk
Gustav Akk
Ivermectin (IVM) is a widely used antiparasitic drug that acts through allosteric activation and potentiation of the glutamate-gated chloride channel present in neurons and muscle cells of helminths and insects. In mammals, IVM activates several members of the Cys-loop ion channel family, including the GABAA receptor. Although the centrally located GABAA receptors are protected against the actions of IVM by the transporter protein P-glycoprotein 1 present in the blood-brain barrier, many peripheral GABAA receptors are exposed to blood-borne IVM. Here, we have investigated the activating and modulatory effects of IVM on α5β3γ2L and α1β3γ2L GABAA receptors expressed in Xenopus oocytes. We show that IVM is a potent and efficacious agonist of the α5β3γ2L receptor with an EC50 of 0.06 μM and a maximal probability of being in the active state >0.3. IVM, unlike typical agonists of the GABAA receptor, does not desensitize the receptor even in 20-minute-long applications. Receptors desensitized by high concentrations of GABA are reactivated upon exposure to IVM. Coapplication of IVM with GABA or the allosteric agonist, etomidate, manifests as simple additivity of individual responses rather than potentiation. The application of the allosteric agonist, pentobarbital, is without effect or reduces the response to IVM. Overall, GABAA receptor activation by IVM exhibits a number of unique properties not encountered with commonly used or studied GABAergic drugs. SIGNIFICANCE STATEMENT: Peripheral GABAA receptors are accessible to the widely used antiparasitic agent ivermectin (IVM). This study shows that IVM activates the α5β3γ2L and α1β3γ2L subtypes at therapeutic concentrations. Responses to IVM are not potentiated by the transmitter GABA or the allosteric agonists etomidate or pentobarbital. Receptors activated by IVM do not exhibit desensitization, while receptors desensitized by GABA are reactivated upon exposure to IVM.